SHEET 1 OF 1 ATTORNEY'S DKT NO. APPLICATION NO. Substitute for form 1449A/PTO 033052-004 09/892,327 APPLICANT INFORMATION DISCLOSURE Zhang et al. STATEMENT BY APPLICANT FILING DATE GROUP June 26, 2001 1645

KOE		<u> </u>	S. PATENT DOCUMENTS			
3 10	U.S. Patent	Document		,		
Examiner Initials	Number (if known)		Name of Patentee or Applic of Cited Document	l l	Date of Publication (MM-DD-YYYY)	
製造 - 1 (2017年 - 1 (2	Foreign Pater	a North and Jack Sale Constaling	EIGN PATENT DOCUMENT	rs ·		
Examiner Initials	Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	Yes n	
		NON PA	TENT LITERATURE DOCUM	AENTS		
Examiner Initials	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. International Search Report in related PCT application no. PCT/US01/20334, mailed May 15, 2002					
	Bartulewicz, D., et al., "Synthetic Analogues of Netropsin and Distamycin-Synthesis of a New Pyridine and Carbocyclic Analogues of the Pyrrolecarboxamide antitumor antibiotics", <i>Acta Biochimica Polonica</i> , Vol. 45, No. 1, pp. 41-57 (1998).					
	Bielawski, K., et al., "Synthetic Analogues of Netropsin and Distamycin III Synthesis of a Pyrid Analgue of the Pyrrolecarboxamide Antitumor Antibiotics", <i>Roczniki Akademii Medycznej w Bialymstoku</i> , Vol. 41, No. 2, pp. 293-304 (1996).					
	Chowdhury, AK, et al., "Synthesis and Evaluation of Bix-Dipeptide and Bis-Tripeptide Analog of Actinomycin D", <i>Jol. of Medicinal Chem.</i> , Vol. 21, No. 7, pp. 607-612 (1978).					
Vw)	_	P, et al., "Searc P-002194807 (19	h for Antitumor Compound 997).	ls Among Actinocin Deriv	atives", Che	
•	 					
		_				

JUN 2 4 2002

TECH CENTER 1600/2900

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.